Reliability, Satisfaction and Effectiveness of Benralizumab Home Self-Administration in Patients with Severe Eosinophilic Asthma in Real-World Practice: The Auto-Benra Study

Figures & data

Figure 1 Subcutaneous administration assessment questionnaire (SQAAQ).

Notes: Adapted from Callis Duffin K, Bukhalo M, Bobonich MA, et al. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices (Auckl). 2016;9:361–369.²⁰ Copyright © 2016 Callis Duffin et al. Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).

Table 1 Baseline Demographic and Clinical Characteristics of AUTO-BENRA Study

Demographics Characteristics		N Missed
Age y, mean±SD	57.31±9.97
Female, n (%)	34 (62.96%)
Educational level
High school n (%)	9 (18.75%)
Vocational training n (%)	14 (29.17%)
Secondary education n (%)	17 (35.41%)
Primary education n (%)	8 (16.67%)
BMI mean±SD	28.04±4.62	1
Current/ex- smoker >10p/year n (%)	9 (16.7%)
Comorbidities
GERD n (%)	32 (59.26%)
OSAS (%)	5 (9.26%)
Mental disorders n (%)	13 (24.07%)
Bronchiectasis n (%)	11 (20.37%)
Nasal polyps n (%)	25 (26.3%)
AERD n (%)	16 (30.7%)
Aeroallergen’s sensitization-atopy n (%)	38 (70.37%)
Biomarkers
Total IgE KU/L mean ±SD	554.21±1337.22
Eosinophils Cells /microliter ±SD	742.04±441.73
Clinical Characteristics
Prednisone-dependent patients n (%)	24(44.4%)
Severe exacerbation rate Exacerbations/year ±SD
FEV1 percentage mean ±SD	68.82±15.92%	2
ACT points mean±SD	14.10±4.41	2
MiniAQLQ mean ±SD	3.99±1.30	26

Abbreviations: BMI, body mass index; GERD, gastroesophageal reflux disease; OSAS, obstructive sleep apnea syndrome; AERD, aspirin-exacerbated respiratory disease; FEV₁, forced expiratory volume in first second; ACT, asthma control test; MiniAQLQ, reduced version of asthma quality of life questionnaire.

Table 2 Summary of SQAAQ and VAS Score

	Total		Prefilled Syringe			Autoinjector		p-value
	N= 54	N missed	N=27		Nmiss	N=26	N missed
Device		0
Prefilled syringe	27 (50.94%)
Autoinjector	26 (49.06%)
Global VAS patient	9.37 (0.99)	1	9.38 (0.64)	26	1	9.35 (1.26)	0	0.89
Patient VAS	9.38 (1.03)	1	9.50 (0.86)	26	1	9.27 (1.19)	0	0.43
Physician VAS	9.44 (0.92)	1	9.58 (0.58)	26	1	9.31 (1.16)	0	0.29
Average 12-SQAAQ	6.89 (0.16)	0	6.90 (0.16)	27	0	6.89 (0.16)	0	0.87

Figure 2 Improvement on subtypes of exacerbations rate after benralizumab.

Callis Duffin K, Bukhalo M, Bobonich MA, et al. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices. 2016;9:361–369. doi:10.2147/MDER.S113752

 Google Scholar